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Background:  A new  HIV diagnostic  algorithm  has  been  proposed  which  replaces  the  use  of  the  HIV-1
Western  blot  and  HIV-1  immunoﬂuorescence  assays  (IFA)  as  the  supplemental  test  with  an  HIV-1/HIV-2
antibody  differentiation  assay.
Objectives:  To  compare  an FDA-approved  HIV-1/HIV-2  antibody  differentiation  test  (Multispot)  as  a  con-
ﬁrmatory  test  with  the  HIV-1  Western  blot  and  IFA.
Study  design:  Participants  were  screened  with  an  HIV-1/HIV-2  combination  Antigen/Antibody  (Ag/Ab)
screening  assay.  Specimens  with  repeatedly  reactive  results  were  tested  with  Multispot  and  either  West-
ern blot  or  IFA.  Specimens  with  discordant  screening  and  conﬁrmatory  results  were  resolved  with  HIV-1
RNA  testing.
Results:  Individuals  (37,876)  were  screened  for HIV  infection  and  654  (1.7%)  had  a  repeatedly  reactive
Ag/Ab  assay  result.  On  Multispot,  554  (84.7%)  were  HIV-1  reactive,  0  (0%)  were  HIV-2  reactive,  1  (0.2%)
was  reactive  for  both  HIV-1  and  HIV-2  (undifferentiated),  9  (1.4%)  were  HIV-1  indeterminate,  and  90
(13.8%)  were  non-reactive.  HIV-1  RNA  was  detected  in  47/90  Multispot  non-reactive  (52.2%)  specimens.
Among  specimens  conﬁrmed  to have  HIV  infection  (true positives),  Multispot  and  Western  blot  detected
HIV-1 antibody  in  a  similar  proportion  of  cases  (93.7%  vs. 94.4%  respectively)  while  Multispot  and  IFA
also  detected  HIV-1  antibody  in  a  similar  proportion  of  cases  (84.5%  vs. 83.4%  respectively).
Conclusions:  In this  study,  Multispot  conﬁrmed  HIV  infections  at a  similar  proportion  to  Western  blot  and
IFA. Multispot,  Western  blot,  and  IFA,  however,  did  not  conﬁrm  all  of  the  reactive  Ag/Ab  assay  results  and
underscores  the  importance  of  HIV  NAT  testing  to  resolve  discordant  screening  and  conﬁrmatory  results.© 201
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solely reactive in 0.92% (6/654) and the gp41 peptide spot (HIV-1)M.W. Pandori et al. / Journal of Clin
. Background
The current HIV diagnostic algorithm (published in 1989) con-
ists of a repeatedly reactive HIV immunoassay followed by a
upplemental test for conﬁrmation, such as the Western blot or
ndirect immunoﬂuorescence assay (IFA) [1]. Early HIV immunoas-
ays used either viral lysate antigens (ﬁrst generation) or synthetic
eptides and recombinant antigens (second generation) and
etected only immunoglobulin G (IgG)-class antibodies. Most labo-
atories now use either third-generation immunoassays that detect
oth IgM-class and IgG-class antibodies or fourth-generation com-
ination antigen/antibody immunoassays that detect both classes
f antibody and also p24 antigen (a major core protein of HIV).
gM-class antibody and p24 antigen can be detected early, before
gG-class antibody appears, decreasing the window period between
ime of infection and the time that infection can be detected by
creening [2]. Additionally, these newer HIV immunoassays detect
ntibodies to HIV-2 in addition to HIV-1, but are unable to differ-
ntiate them from HIV-1 antibodies. Although these advances have
ccurred with screening immunoassays, the supplemental testing
ptions available in the U.S., Western blot and IFA, have remained
he same: both are unable to detect IgM-class antibody and p24
ntigen and are unable to reliably detect (or differentiate) HIV-2
ntibody [3,4]. To improve HIV diagnosis, a new HIV diagnostic
esting algorithm has been proposed [5–7]. The new diagnostic
lgorithm evaluated in this study replaces the WB  with an HIV-
/HIV-2 antibody differentiation assay as the supplemental test
nd includes an RNA test to resolve reactive immunoassay with
egative supplemental test results [5–8]. In retrospective studies,
his algorithm can be performed more rapidly than the current
IV diagnostic algorithm, can detect acute HIV-1 infections, and
an diagnose unsuspected HIV-2 infections [7,9]. As of March 25,
013 in the U.S., the Multispot HIV-1/HIV-2 Rapid Test (Multispot)
s FDA-approved as the second test (after a repeatedly reactive
IV immunoassay) to diagnose HIV infection as part of a testing
lgorithm [10]. Multispot consists of a single-use, ﬂow-through car-
ridge whereupon a rapid immunoassay is performed on a ﬁlter
ubstrate. The assay is a rapid (∼15 min) qualitative immunocon-
entrating assay that detects and differentiates antibody against
IV-1 and HIV-2 in serum or plasma. Two “spots” on the ﬁlter
onsist of recombinant HIV-1 gp41 and a peptide containing an
mmunodominant epitope of HIV-1 gp41, respectively. A third spot
onsists of a peptide containing an immunodominant epitope of
IV-2 gp36. A fourth spot consists of goat anti-human IgG, which
erves as a methodological control [10]. Given the importance of
ultispot in the new HIV diagnostic algorithm, we  compared the
erformance of this assay as a supplemental test after a repeatedly
eactive immunoassay result with the performance of Western blot
nd IFA.
.1. Objectives
To compare an FDA-approved HIV-1/HIV-2 antibody differenti-
tion test (Multispot) as a conﬁrmatory test with the HIV-1 Western
lot and IFA.
. Study design
The Screening Targeted Populations to Interrupt On-going
hains of HIV Transmission with Enhanced Partner Notiﬁcation
STOP) study is a prospective, on-going study evaluating: (1) meth-
ds to detect acute HIV infection and enhance partner services in
ew York City, North Carolina, and San Francisco, California; and (2)
he new HIV diagnostic algorithm. The STOP study was approved
y institutional review boards for the University of California atirology 58S (2013) e92– e96 e93
San Francisco, the University of North Carolina at Chapel Hill, and
the New York City Department of Health & Mental Hygiene, and
by a research determination at CDC. Participants were ≥12 years
of age and receiving HIV testing at one of 12 HIV testing venues
in sexually transmitted infection clinics and community-based HIV
testing programs. Specimens collected between September 1, 2011
and September 1, 2012 were included in this analysis. Data on the
frequency of acute HIV infections detecting during the STOP study
have been published elsewhere [7] but this manuscript is the ﬁrst
evaluation of the performance of Multispot compared with both
Western blot and IFA in the STOP study.
Specimens were screened with the Architect HIV Ag/Ab
Combo Assay (Architect; Abbott Diagnostics, Abbott Park, IL),
a fourth-generation immunoassay, according to manufacturer’s
speciﬁcations. Repeatedly reactive specimens were tested with the
Multispot HIV-1/HIV-2 Rapid Test (Multispot; Bio-Rad Laborato-
ries, Redmond, WA)  and either an HIV-1 Western blot (Bio-Rad
Laboratories) at the New York City and North Carolina testing sites
or an IFA (Sanochemia, Vienna, Austria) at the San Francisco test-
ing site, per package insert. Specimens with negative Multispot,
Western blot or IFA results (discordant screening and conﬁrma-
tory results) were tested for HIV-1 RNA with either Aptima HIV-1
RNA Qualitative Assay (Aptima; Gen-Probe, Inc., San Diego, CA),
a qualitative method of HIV-1 RNA detection with a lower limit
of detection of approximately 30 copies per ml plasma, or m2000
RealTime HIV-1 Quantitative Assay (Abbott Diagnostics), a quanti-
tative test with a lower limit of quantiﬁcation of 40 copies per ml
plasma [11].
Multispot results were determined according to the manufac-
turer’s new speciﬁcations [10]. The differentiation assay has four
reaction spots including control, HIV-2 peptide, recombinant HIV-
1, and HIV-1 peptide. Test results that did not develop a color
reaction at the control spot were interpreted as invalid. Specimens
with both HIV-1 spots (recombinant and peptide) reactive were
interpreted as HIV-1 reactive. Specimens with only one HIV-1 spot
(either recombinant or peptide) reactive were interpreted as HIV-1
indeterminate. Specimens with a reactive HIV-2 spot were inter-
preted as HIV-2 reactive. Specimens with both HIV-1 and HIV-2
spots reactive that could not be resolved with dilutional testing
were interpreted as HIV antibodies detected (undifferentiated).
Finally specimens with only a reactive control spot were inter-
preted as negative for HIV-1 and HIV-2 antibodies.
The primary analysis described and compared the frequencies
of Multispot, Western blot, and IFA results among participants
with repeatedly reactive fourth-generation immunoassay results.
All analyses were performed using SAS version 9.3 (SAS Institute
Inc., Cary, NC, USA). McNemar’s exact test was used to test for dif-
ferences in proportions (categorical variables) between the tests.
Statistical signiﬁcance was  indicated by a p-value <0.05.
3. Results
From September 1, 2011 to September 1, 2012, 37,876 par-
ticipants were screened with the Architect fourth-generation
immunoassay at 12 testing venues. Overall, 654 (1.7%) specimens
were found to be repeatedly reactive (positive) and were tested
with Multispot (Fig. 1). No Multispot results were invalid. Multispot
was  reactive for both HIV-1 speciﬁc spots (HIV-1 Reactive) in 84.7%
(554/654) of specimens. The recombinant gp41 spot (HIV-1) waswas  solely reactive for 0.46% (3/654) of specimens. There was one
specimen (0.2%) with both HIV-1 spots and the HIV-2 spot reactive
despite repeat testing at a 1:10 dilution and a 1:100 dilution as spec-
iﬁed in the product insert; these results were interpreted as HIV
e94 M.W. Pandori et al. / Journal of Clinical Virology 58S (2013) e92– e96
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sig. 1. Multispot rapid HIV-1/HIV-2 differentiation assay results with the new HIV
011–2012.
ntibody detected but undifferentiated.2 Multispot was negative
or 13.8% (90/654) specimens.
The nine Multispot HIV-1 indeterminate specimens (6 with the
ecombinant gp41 spot only and 3 with the gp41 peptide spot only)
ere tested for HIV-1 RNA. Of these, 8/9 (88.9%) had detectable
IV-1 RNA. The one specimen without detectable HIV-1 RNA was
lso negative by Western blot. This participant was retested one
eek later and on repeat testing had a negative Architect fourth-
eneration immunoassay result and undetectable HIV-1 RNA.
On initial Multispot testing, 19 (2.9%) specimens had both HIV-1
pots and the HIV-2 spot reactive consistent with a result positive
or HIV antibodies, but undifferentiated for HIV-1 and HIV-2. After
 1:10 dilution, 17 of these specimens were found to be reactive
or both HIV-1 spots but HIV-2 non-reactive. After a 1:100 dilution,
ne further specimen resolved to reactive for both HIV-1 spots but
IV-2 non-reactive. HIV-1 Western blot was performed on 13 of
he 18 specimens that resolved by dilution and all 13 were HIV-
 positive (100%). IFA was performed on the other ﬁve specimens
hat resolved with dilution and all ﬁve were HIV-1 positive by IFA
100%). The one specimen that was not differentiated by either 1:10
r 1:100 dilutions was found to be HIV-1 Western blot positive,
IV-1 RNA detectable, HIV-2-speciﬁc immunoassay reactive, and
IV-2 Western blot positive consistent with a potential dual HIV-
/HIV-2 infection.
Overall 90 (13.8%) of the 654 Architect fourth-generation
mmunoassay reactive specimens were non-reactive by Multispot.
f these, 47/90 (52.2%) had detectable HIV-1 RNA consistent with
2 There were 18 additional specimens that were undifferentiated on initial testing
hat  resolved to HIV-1 reactive after a 1:10 (n = 17) or 1:100 (n = 1) dilution. These
esults are included in the HIV-1 antibodies detected in Fig. 1 and are discussed
eparately in the results below.ostic testing algorithm – New York, San Francisco, and North Carolina, September
an acute HIV-1 infection and 43 (47.8%) did not have detectable
HIV-1 RNA consistent with a false-positive HIV screening test.
These acute HIV infections accounted for 7.7% of the 610 HIV infec-
tions that could be conﬁrmed by either Multispot or HIV-1 RNA
testing (Fig. 1). Among these 47 specimens with detectable HIV-1
RNA, 22 were tested by Western blot of which two  (9.1%) were pos-
itive, ﬁve (22.7%) were indeterminate, and 15 (68%) were negative.
The other 25 specimens with detectable HIV-1 RNA were tested
with IFA of which two were positive, one (4.0%) was  indetermi-
nate, and 22 were negative. Overall, 43 of 47 (91.5%) specimens
were negative or indeterminate by Multispot and either Western
blot or IFA despite having detectable HIV-1 RNA.
By combining Multispot and HIV-1 RNA results, 610 (93.3%) of
654 Architect fourth-generation immunoassay reactive specimens
were conﬁrmed to be consistent with HIV infection. Of these 610
specimens, 429 were tested by Western blot and Multispot and
181 were tested by IFA and Multispot (Table 1). Among the 429
specimens tested by Western blot, Multispot conﬁrmed infection
in 4023 (93.7%; 95% conﬁdence intervals [CI]: 91.4–96.0%) cases
while the Western blot conﬁrmed infection in 405 (94.4%; 95% CI:
92.2–96.6%) cases (p = 0.55 by exact McNemar’s test). Multispot and
Western blot results were concordant in 96.3% of cases. Among
Multispot HIV-1 reactive specimens (n = 401), there was one (0.25%)
Western blot-negative result. Among Western blot-positive spec-
imens (n = 405), there were two  (0.5%) Multispot-negative results.
Among these conﬁrmed HIV infections (n = 429), Multispot and
Western blot also had similar frequencies of negative (n = 22 vs.
n = 16 respectively) and indeterminate (n = 5 vs. n = 8 respectively)
results.
3 Including 401 results with “HIV-1 antibodies detected” and one result with “HIV-
1  and HIV-2 antibodies detected”.
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Table 1
Multispot rapid HIV-1/HIV-2 differentiation assay results compared with Western blot and immunoﬂourescence assay results among specimens with
conﬁrmed HIV infection (n = 610) – New York, San Francisco, and North Carolina, September 2011–2012.
HIV-1  antibod ies 
detected (n= 554)
HIV-1  and  HIV-2 
antibodies detected (n=1)
HIV-1  ind eterminate 
(n=8*)
Negati ve for HIV 
antibodies (n= 47**)
   (n=5)  (n=1)  (n=401)Western blot          (n=429)    (n=22)
  1 (100%)  397 (99.0%)  Positive                (n=405)     2 (9%)  5 (100%)
  0 (0%)  0 (0%)      3 (0.75%)  Indeterminate       (n=8)     5 (23%)
  0 (0%)      1 (0.25%)  Negative               (n=16)   15 (68%)  0 (0%)
  (n=153)Immunoflourescence assay (n=181)    (n=25)   (n=3)
   -  147 (96.1%)  Positive                 (n=151)      2 (8%)  2 (67%)
  1 (33%)   -      5 (3.3%)  Indeterminate        (n=7)      1 (4%)
  0   (0%)   -      1 (0.6%)  Negative                (n=23)    22 (88%)
Multispot Rapid HIV-1/HIV-2 Differentiation Assay Results
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* HIV-1 indeterminate result with a negative HIV-1 RNA NAT result was  e
**  Only specimens with a reactive HIV-1 RNA NAT were included.
Among the 181 specimens tested by IFA, Multispot conﬁrmed
nfection in 153 (84.5%; 95% conﬁdence intervals [CI]: 79.3–89.8%)
ases while the IFA conﬁrmed infection in 151 (83.4%; 95% CI:
8.0–88.8%) cases (p = 0.75 by exact McNemar’s test). Multispot and
FA were concordant in 93.9% of cases. Among Multispot HIV-1 reac-
ive specimens (n = 153), there was one (0.7%) IFA-negative result.
mong IFA-positive specimens (n = 151), there were two  (1.3%)
ultispot-negative results. Among these conﬁrmed HIV infections
n = 181), Multispot and IFA also had similar frequencies of nega-
ive (n = 25 vs. n = 23 respectively) and indeterminate (n = 3 vs. n = 7
espectively) results.
. Discussion
Since 1989, the Western blot and IFA have been the recom-
ended supplemental antibody tests for conﬁrming reactive HIV
mmunoassay test results [1]. On March 25, 2013, the Food and
rug Administration (FDA) approved a modiﬁcation of the package
nsert for the Multispot HIV-1/HIV-2 Rapid Test so that it can be
sed as the second test (after a repeatedly reactive HIV immunoas-
ay) to diagnose HIV infection as part of a testing algorithm4 [10].
n this prospective study, Multispot conﬁrmed a similar proportion
f HIV infections as Western blot and IFA. Although there was a
igh concordance between Multispot and both Western blot and
FA for positive and negative results, these assays were not able to
onﬁrm all of the Architect fourth-generation immunoassay reac-
ive results. HIV-1 RNA testing identiﬁed an additional 47 acute
IV infections (7.7% of the total HIV infections diagnosed) under-
coring the importance of nucleic acid testing for specimens with
iscordant screening (reactive) and conﬁrmatory (negative) results
egardless of which supplemental test is used.
The new HIV diagnostic algorithm which was evaluated in
his study replaces the Western blot with an HIV-1/HIV-2 anti-
ody differentiation assay (Multispot) as the supplemental test and
ncludes an HIV-1 RNA test to resolve reactive immunoassay with
egative supplemental test results [5–8]. The advantages of this
ulti-test algorithm over the use of Western blot or IFA only as
he supplemental test after a reactive immunoassay include that
t can detect acute HIV-1 infections and can diagnose unsuspected
IV-2 infections [7,9]. In addition, the fast turnaround time for test
esults from the Multispot rapid test (15 min) affords the oppor-
unity to deliver same-day deﬁnitive test results to the majority
f HIV-infected persons who are antibody-positive. Although these
4 The FDA approved Multispot as an HIV screening test in 2005.ed.
advantages are signiﬁcant, it is also important that Multispot does
not sacriﬁce sensitivity for detecting HIV-1 antibody compared
with Western blot and IFA. Data from this analysis indicates that
Multispot’s sensitivity is similar to both the Western blot and IFA.
These results are consistent with previous studies comparing Mul-
tispot and Western blot. [9,12,13] While these previous studies also
demonstrated the ability of Multispot to accurately conﬁrm HIV
infection they did not include a comparison of Multispot to IFA.
The most important performance characteristic of a supplemen-
tal test in a multi-test algorithm is speciﬁcity. In this analysis none
of the Multispot results that were reactive for HIV-1 antibodies
were determined to be false-positive suggesting that Multispot has
similar speciﬁcity to Western blot and IFA (these assays also had no
false-positive results). One Multispot HIV-1 indeterminate result,
however, was determined to be negative for HIV infection. This
specimen was positive for only one of two  HIV-1 speciﬁc spots, the
gp41 peptide spot. As per the new HIV diagnostic algorithm and
the FDA-approved package insert, HIV-1 indeterminate results are
tested for HIV-1 RNA [10]. The false-reactive HIV-1 indeterminate
result that was  observed in this study validates this recommenda-
tion for HIV-1 RNA testing in these indeterminate situations.
While the performance characteristics of Multispot as a supple-
mental test was  similar to both Western blot and IFA, it is important
to highlight that none of these three supplemental tests were
capable of conﬁrming all of the HIV infections diagnosed in this
study. Fourth-generation HIV immunoassays detect p24 antigen
(in addition to IgG- and IgM-classes of antibody) which becomes
detectable early during HIV infection, before antibody appears,
allowing the fourth-generation immunoassays to identify some
HIV infections in the acute phase [7,13,14]. In this study, approx-
imately half of the Multispot-negative specimens had detectable
HIV-1 RNA consistent with acute HIV infection. Although some
studies have suggested that Multispot is more sensitive for recent
infection than the Western blot, perhaps due to the fact that a
higher volume of serum or plasma is analyzed by the test [2,15],
we did not observe an advantage in this study. Overall, these results
underscore the importance of using a multi-test algorithm where
discordant screening (reactive) and supplemental (negative) test
results can be resolved with HIV-1 RNA testing. The detection of
acute infection depends upon including HIV-1 RNA testing and is
particularly important as this highly infectious phase contributes
disproportionately to HIV transmission [16,17].The ﬁndings in this study are subject to at least two limita-
tions. First, only one potential HIV-2 infection was  detected which
limited our ability to evaluate the impact of HIV-2 diagnosis in
this comparison. Second, participants in the STOP study were a
e ical V
c
a
t
a
i
m
p
b
H
o
s
t
s
c
a
t
F
C
i
E
A
t
e
P
(
H
H
R
[
[
[
[
[
[
[
et  al. Ampliﬁed transmission of HIV-1: comparison of HIV-1 concentrations in96 M.W. Pandori et al. / Journal of Clin
onvenience sample of persons at high risk for HIV infection and
 high frequency of acute HIV infections was detected. Although
his relatively high prevalence of acute HIV infections should not
ffect the comparison of Multispot with Western blot and IFA, it is
mportant for clinicians to realize that negative Multispot results
ay  not correlate with acute HIV infections as frequently in low
revalence settings.
Multispot is an important diagnostic advance that differentiates
etween HIV-1 and HIV-2 infections and improves the timeliness of
IV testing. Multispot can be used as a supplemental test (the sec-
nd test) in the new HIV diagnostic algorithm. In this prospective
tudy, Multispot conﬁrmed a comparable proportion of HIV infec-
ions and was highly concordant with the Western blot and IFA. This
tudy also demonstrated that discordant screening (reactive) and
onﬁrmatory (negative) results occur with all of the supplemental
ssays and that HIV-1 RNA testing is necessary in these situations
o detect acute HIV-1 infections.
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